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Abstract 
 
Background: Faecal calprotectin (FC) measurement distinguishes patients with inflammatory bowel 
disease (IBD) from those with irritable bowel syndrome but evidence of its performance in primary 
care is limited. 
 
Objective: To assess the yield of IBD from FC testing in primary care.  
Methods: Retrospective review of hospital records to assess the outcome following FC testing in 
primary care. Investigations for all patients undergoing FC testing in a single laboratory for six months 
from 1.10.13 to 28.2.14 were reviewed. 
Results: 410 patients (162 male; median age 42; range 16-91) were included. )& !ȝJJ ZDV
considered positive (FC+). 148/410 (36.1%; median age 44 (17-91)) were FC+ (median FC ȝJJ
(51-1770)). 122/148 FC+ patients (82.4%) underwent further investigation. 97 (65.5%) underwent 
lower GI endoscopy (LGIE), of which 7 (7.2%) had IBD. 49/262 (18.7%) FC negative (FC-) patients 
(FC чȝJJ (median age 47 (19-76)) also underwent LGIE, of whom 3 (6.1%) had IBD. 
IBD was GLDJQRVHG LQ    XOFHUDWLYH FROLWLV  &URKQ¶V GLVHDVH, 4 microscopic colitis). 
8/11 were FC+ (range 67±1170) and 3 FC-$WDȝJJWKUHVKROGVHQVLWLYLW\IRUGHWHFWLQJ,%'ZDV
72.7%, specificity 64.9%, positive predictive value (PPV) 5.41%, negative predictive value 98.9%. 
,QFUHDVLQJWKHWKUHVKROGWRȝJJUHGXFHGWKHVHQVLWLYLW\RIWKHWHVWIRUGHWHFWLQJ,%'WR 
Conclusion: FC testing in primary care has low sensitivity and specificity with poor PPV for 
diagnosing IBD. Its use needs to be directed to those with a higher pre-test probability of disease. 
Local services and laboratories should advise general practitioners accordingly. 
Keywords: Faecal Calprotectin, inflammatory bowel disease, colonoscopy, primary health care 
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Introduction 
 
Calprotectin is a neutrophil protein, the measurement of which, in faeces, detects intestinal 
inflammation1. Measurement of faecal calprotectin (FC), in people with gastrointestinal symptoms is 
thought to be useful in identifying those at a higher risk of harbouring inflammatory bowel disease 
,%'LQFOXGLQJXOFHUDWLYHFROLWLVDQG&URKQ¶VGLVHDVH2.  
 
FC testing has been recommended for those with new lower gastrointestinal symptoms, to help 
differentiate IBD and irritable bowel syndrome2 and when symptoms suspicious for cancer3 were 
absent. These guidelines emphasised the importance of appropriate local pathways of care and 
quality assurance and raised a series of hitherto unanswered questions relating to referral and 
investigation following FC testing in primary care. These questions included the proportion of patients 
with a raised FC who undergo further gastrointestinal investigation including which investigations are 
undertaken, how many of those investigations subsequently lead to a diagnosis of IBD when FC 
testing is used in primary care, the sensitivity and specificity of FC testing, the numbers of tested 
patients undergoing colonoscopy and the diagnostic yield of these colonoscopies2. Such information 
is of central importance in understanding the position of FC testing in a diagnostic pathway, utilising 
laboratory services, and  which starts with patients in primary care.  
 
This study was therefore undertaken to assess the diagnostic accuracy of FC in the detection of IBD 
in a primary care setting following the introduction of the test to the Sheffield Teaching Hospitals Trust 
in October 2013. 
 
Methods 
 
Patients
Consecutive patients who had a FC measurement undertaken in the Immunology Laboratories of the 
Sheffield Teaching Hospitals NHS Foundation Trust between 01/10/13 and 28/02/14 were identified.  
Subsequent inclusion in this evaluation is outlined in Figure 1. Patients aged under 16 years (n=4), 
those with known IBD (n=23) (as identified from clinic letters and investigations) and where FC testing 
was initiated in secondary care (n=57), were excluded from the study. Further investigations had 
therefore not been undertaken at the time of FC testing. 
 
Where patients had raised FC levels but no identifiable further assessment, their general practitioners 
(GPs) were approached by letter for information about further investigations (n=20). Patients for 
whom no reply was received were also excluded from the study (n=6).  
 
For those who had repeated FC measurements over the inclusion period, the first FC measurement 
initiated by the GP was used for analysis.   
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Measurement of FC 
 
FC was measured by IDK® Calprotectin ELISA (Immunodiagnostik, Germany). The normal range (FC 
negative) in adults was taken as ч50 µg/g faeces2. Results of testing were available to those 
accepting referrals and at the point of subsequent diagnoses. 
 
Identification of further investigations and hospital assessments following FC testing 
 
Using patient administration systems and laboratory databases, we retrospectively identified 
investigations undertaken. These included blood tests for erythrocyte sedimentation rate (ESR) and c-
reactive protein (CRP) within 2 months before or after FC testing and follow-up imaging or endoscopic 
evaluation within 18 months. Hospital assessment at our centre within 12 months following the FC 
test by a gastroenterologist, colorectal or upper gastrointestinal surgeon was also identified from 
hospital records. 
 
Lower GI Endoscopy and Imaging 
 
Positive findings on lower GI endoscopy were defined as identification of IBD, colorectal cancer or 
adenomas. Positive findings on further imaging included evidence of diagnoses such as diverticulitis 
and appendicitis. All other findings were defined as non-significant. A diagnosis of IBD was made on 
the basis of typical histological features in biopsies taken at lower GI endoscopy, typical radiological 
features4,5 or accepted diagnostic appearances at small bowel video capsule endoscopy6,7  
 
Statistics 
Descriptive statistics are presented as the mean or median (as appropriate). Categorical data was 
analysed using a chi squared test, continuous data with either t-test (normally-distributed data) or 
Mann Whitney U test (non-parametric data), where statistical significance was considered as p<0.05. 
Analyses were performed using Statistical Package for the Social Sciences ((SPSS), IBM, Somers, 
USA. Version 22.0). Bonferroni¶VFRUUHFWLRQwas used for multiple univariate tests, with p<0.007 being 
regarded as significant for comparison of rates for different investigations between FC positive and 
FC negative patients (Figure 3).  Exploratory assessment of sensitivity, specificity, positive and 
negative predictive value at differing FC thresholds was also undertaken. Receiver operating 
characteristic (ROC) curves were also derived for the diagnosis of IBD or organic disease, using the 
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ROCR package in the R environment for statistical computing and the area under the curve 
(AUROCC) calculated8. 
 
The study was undertaken as Sheffield Teaching Hospitals NHS Foundation Trust, Clinical 
Effectiveness Unit Service Evaluation, Reference 6509, December 2014. 
 
Results 
  
500 patients were identified of whom 410 patients (162 male) were included in the analysis (Figure 1). 
The median age was 42 (range 16-91).  148 patients had positive FC levels (median FC 116.5 µg/g 
faeces (range 51-1770)), with a median age of 44 years (range 17-91). 262 were FC negative 
(median FC 19 µg/g faeces (range 0-50)), with a median age of 40 years (range 16-88). 
 
Faecal Calprotectin Levels 
 
The overall distribution of FC values in the study cohort is shown in Figure 2. 
 
Referral to secondary care 
 
196/410 patients (47.8%) underwent referral to a gastrointestinal specialist. Of these, 126 (64.3%) 
had a raised FC. FC positive patients were significantly more likely to be referred to secondary care 
(126/148 (85.1%)) than those with a FC negative result (70/262 (26.7%)) (p<0.001).  
  
Investigations 
 
Further investigation in the FC positive and FC negative groups is shown in Figure 3. 97/148 (65.5%) 
of FC positive patients underwent lower GI endoscopy (90 colonoscopies, 7 flexible sigmoidoscopies) 
compared to 49/262 (18.7%) FC negative patients (43 colonoscopies, 6 flexible sigmoidoscopies). 
 
49 patients FC negative patients still underwent lower GI endoscopy and were significantly older 
(median age 47 (range 19-76)) than FC negative patients who did not undergo colonoscopy (median 
age 39 (range 16-88) (p=0.002)). 
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80/97 (82.5%) of FC positive patients were found to have no significant abnormality at lower GI 
endoscopy compared to 44/49 (89.8%) FC negative patients who had lower GI endoscopy (p=0.33). 
 
94 (63.5%) FC positive and 142 (54.2%) FC negative patients had CRP testing ± with higher values in 
the FC positive patients (median 3.1 (range 0-87)) than in the FC negative patients (1.3 mg/L (range 
0-105)) respectively, (p<0.001). 94 (63.5%) FC positive patients and 151 (57.6%) FC negative 
patients had ESR measured with respective median values of 7 mm/hr (range 2-41) and 5mm/hr (2-
95) (p=0.009). 
 
Diagnosis of IBD  
 
11/410 (2.6%) patients who underwent FC testing were diagnosed with new IBD (Table 1). For newly 
diagnosed IBD, the sensitivity and specificity for the pre-specified diagnostic threshold are shown in 
Table 2, alongside values from existing experience in this field, including secondary care studies used 
to develop NICE guidance. 
The performance of the test using different thresholds of abnormality is described in Table 3. Altering 
the threshold DWZKLFK)&LVUHJDUGHGDVµSRVLWLYH¶ did not affect the performance at the thresholds 
considered.  
The ROC curve for the performance of FC in diagnosing IBD is given in Figure 4a. The AUROCC was 
0.69.  
The accuracy (number of true positive tests + number of true negative tests as a proportion of all 
tests) in diagnosing IBD is shown in Figure 5, with poor accuracy below a threshold of 250 µg/g 
faeces. Only 30 of the cohort had FC levels > 250µg/g and only 3 of these had a diagnosis of IBD. 
Other diagnoses 
 
In addition to those diagnosed with IBD, a number of positive diagnoses of organic disease were 
made following endoscopic and radiological investigation. Of those who were FC+, 2 patients had 
colorectal cancer, 8 colorectal adenomatous polyps, 1 diverticulitis, 1 appendicitis. One FC+ patient 
had a final diagnosis of diversion proctitis, but it was felt that the FC result obtained from the proximal 
stoma could not reflect that diagnosis, and so was not included as having detected IBD. Of those who 
were FC-, 2 had colorectal adenomatous polyps and 1 appendicitis. The ROC curve for the 
performance of FC in diagnosing organic disease is given in Figure 4b. The AUROCC was 0.76. 
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Discussion 
 
We have described the experience of primary care FC testing in a single, predominantly urban area. 
This has highlighted low sensitivity and specificity for the detection of IBD and a high rate of negative 
endoscopic investigations.  
 
The introduction of FC testing has been considered an opportunity to reduce unnecessary 
gastrointestinal investigation in people suspected of having IBD2. The current study was undertaken 
to examine the outcome of its use in a routine primary care setting, where there is limited information7 
with only two studies assessing its sensitivity and specificity9,10. Pavlidis et al  showed high sensitivity 
and specificity of FC testing in primary care (82% and 77%, respectively)9. However, the performance 
of the test was assessed in differentiating organic from non-organic disease, rather than IBD from 
non-IBD. Patients were younger, with a median age of 33 compared to 42 in the current study. This 
may have contributed to the lower sensitivity and specificity of 72.7% and 64.9% respectively in our 
study, where differentiation of IBD from non-IBD was assessed. If other organic diagnoses are 
included, the sensitivity increases to 78% and the specificity to 69%. The age range of patients in the 
current study also included a number of elderly patients where the yield of IBD may be lower and 
investigation for other pathology, especially cancer, may have been required irrespective of FC result. 
 
We have shown lower sensitivity and specificity for FC testing in primary care than in secondary care, 
where a meta-analysis of five studies used by NICE to create DG112 gave sensitivity and specificity 
values of 93% and 94%, respectively, when distinguishing IBS and IBD. In addition, the sensitivity 
values increased to 100% when comparing IBD versus non-IBD. However, eight of eleven studies 
included in the meta-analysis were paediatric studies. The PPV of 5.4% seen in our study is also 
lower than other studies. This may be due to the lower prevalence of IBD in our primary care 
population at 2.6%, than in a secondary care cohort. Importantly however, the NPV was high at 
98.9%, VXJJHVWLQJDUROHIRU)&WHVWLQJDVDµUXOH-RXW¶WHVWIRU,%'.  64% of FC results were negative 
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and a further 16% fell between 51 and 100 µg/g. This distribution may have skewed the NPV. The 
skewed distribution might reflect that GPs are using the test to aid diagnosis, and that those with 
obvious symptoms of severe IBD may have been referred ± appropriately - without testing. 3/11 
patients diagnosed with IBD had a negative FC, reinforcing the importance of other clinical and 
biochemical findings. Further, only 1 of these 3 patients had small bowel inflammatory disease to 
potentially explain the false negative result.  
 
Over 80% of all people who were investigated by lower GI endoscopy did not have significant 
pathological findings ± in either the FC positive and negative groups. It is possible that FC testing may 
therefore be increasing the number of unnecessary colonoscopies. There are a number of factors 
influencing changes in the numbers of patients referred for colonoscopy and it is not possible to 
determine, from this study, how much the introduction of FC testing contributes to this.  A significant 
number of patients with negative FC values still underwent lower GI endoscopy. This group were 
significantly older than those with a negative FC who did not undergo lower GI endoscopy, suggesting 
that the clinical concern was of cancer. Recent UK guidance recommends that a threshold for FC 
above which colonoscopy should be undertaken is set based on local audit and that measurement 
should not be undertaken in older patients with altered bowel habit11. Increasing demand for 
unnecessary endoscopy has been identified in patients in a secondary care setting though the same 
study also confirmed a high NPV for detecting organic disease for an FC between 100 and 200µg/g11. 
It has also been suggested that incorporating FC measurement into a defined pathway of care ± 
including using a threshold of 250µg/g for fast track investigation and repeat testing for those with 
intermediate results - may improve the PPV for organic disease10. However, we have demonstrated a 
poor accuracy below a FC threshold of 250 µg/g and raising the threshold to 250µg/g reduced 
sensitivity to 27%, which would have left over half of the IBD patients undetected ± and repeat testing 
has not been supported in national guidance11. This poor performance was also demonstrated by the 
low AUROC. The higher PPV may represent a different tested population ± with a lower median age 
and a pathway specifying that cancer was not suspected. In our series, a change in threshold did not 
improve the performance of the test. 
This was a retrospective assessment. Where investigation results were not immediately identifiable, a 
good response was obtained with follow-up letters to general practitioners. There may therefore be a 
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verification bias in this study, as an assumption has been made that those with a negative FC value 
did not develop IBD, if they underwent no further documented assessment. It is possible that patients 
underwent investigation at another centre, or privately, but we feel that the risk of this is small given 
local referral practice. 
 
Details of associated symptoms might have enhanced this study, but would have needed to be 
collected prospectively. It seems likely that, in practice, more focused use of FC testing in particular 
symptom groups ± ie a cohort with higher pre-test probability of IBD - would help improve the 
performance of FC testing. Information on the use of proton pump inhibitors or non-steroidal anti-
inflammatory drug use, which may elevate FC13, 14 was also not available, and it is possible that this 
might have accounted for the normal investigations in those with raised FC. Assessment of FC in 
combination with other markers of inflammation, such as ESR or CRP may be helpful in distinguishing 
those with IBD from other diagnoses. Interestingly, although both ESR and CRP were higher in the 
FC positive patients, the median levels were still close to normal and where IBD was diagnosed, only 
2/7 were associated with a CRP greater than 5mg/L. 
 
Unrestricted FC testing in primary care in this study had lower sensitivity and specificity than in 
secondary care and a poor PPV for diagnosing IBD. Over 80% of all people who were investigated by 
lower GI endoscopy did not have significant pathology and a substantial number of FC negative 
patients still underwent lower GI endoscopy. Studies are therefore required to identify and define the  
population in primary care with a higher pre-test probability of IBD, where FC testing may be more 
discriminatory. In the interim, laboratory services should agree with clinicians local guidelines to 
optimise use of the test. 
Key Messages 
x Unrestricted testing of faecal calprotectin in primary care has a low sensitivity and specificity and 
a poor positive predictive value for diagnosing inflammatory bowel disease (IBD). 
x As a result, over 80% of those with positive faecal calprotectin results had no significant 
abnormality at colonoscopy, which was not significantly different from those who were negative. 
x A raised threshold for colonoscopy to 250µg/g reduces the sensitivity for diagnosing IBD.  
x A different strategy for testing, focusing on those with higher pre-test probability of disease, 
should be developed. 
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Patient Age 
(years) 
UC/CD Diagnosed by Disease extent 
(Montreal 
Classification15) 
FC 
(Pg/g 
faeces) 
CRP 
(mg/L) 
ESR 
(mm/hour) 
1 29 UC Colonoscopy E2  36 3.2 - 
2 19 UC Flexible 
Sigmoidoscopy 
E2  0 - - 
3 26 UC Colonoscopy E1 90 0.9 2 
4 22 UC Colonoscopy E3 1770 - 26 
5 67 CD VCE L1 B2 0 8.5 13 
6 26 CD VCE L3  B1 883 2.4 2 
7 27 CD VCE L4, B1  67 10.6 5 
8 37 Collagenous 
colitis 
Colonoscopy - 157 0.9 2 
9 67 Collagenous 
colitis 
Colonoscopy - 130 8 26 
10 44 Lymphocytic 
colitis 
Colonoscopy - 480 7.6 2 
11 32 Lymphocytic 
colitis 
Colonoscopy - 239 16.7 - 
Median 29  
                         
130 7.6 3.5 
Range 19-67   0-1770 0.9-
16.7 
2-26 
 
Table 1. Clinical and laboratory details of patients diagnosed with inflammatory bowel disease 
following FC testing in primary care. (FC, faecal calprotectin; CRP, C-reactive protein; ESR, 
erythrocyte sedimentation rate; CD, &URKQ¶VGLVHDVH8&, ulcerative colitis; VCE, small bowel 
video capsule endoscopy) 
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 Other Studies 
 
Current Study Pavlidisa 20136 Turvill 20168 NICE DG113: 
Secondary 
Care Meta-
Analysis 
Disease 
differentiation 
For IBD vs 
no IBD 
Organic v 
non-organic 
Organic v  
non-organic 
 
 
Primary or 
secondary 
care setting 
Primary Primary Primary  Primary Secondary 
Threshold for 
positive faecal 
calprotectin 
(µg/g faeces) 
>50 >50 >50 >250 >50 
Sensitivity 72.7%  77.8% 82% 89% 93% 
Specificity 64.9% 66.8% 77% - 94% 
PPV 5.41% 14.2% 28% 40% 5.9% 
NPV 98.9% 97.7% 98% 97% Not stated 
 
Table 2. Summary of sensitivity and specificity of faecal calprotectin testing in current study 
and other studies in primary and secondary care. (IBD = inflammatory bowel disease; PPV 
positive predictive value; NPV negative predictive value ) 
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Faecal 
calprotectin 
threshold for 
abnormal test 
 
Sensitivity Specificity PPV NPV 
> 50Pg/g 72.7% 64.9% 5.41% 98.8% 
> 100Pg/g 54.5% 80.5% 7.14% 98.5% 
> 125Pg/g 54.5% 83.5% 8.33% 98.5% 
> 150Pg/g 45.5% 86.7% 8.62% 98.3% 
> 250Pg/g 27.3% 93.5% 10.3% 97.9% 
 
Table 3. Performance of faecal calprotectin and testing using sensitivity, specificity, positive 
predictive value (PPV) and negative predictive value (NPV) at different thresholds of faecal 
calprotectin for detection of inflammatory bowel disease in patients tested in primary care. 
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Had FC testing 
(n=500) 
410 patients 
included in study 
(n = 410) 
FC +ve and further 
assessment 
(n = 134) 
Included 
GP written to for 
more information 
Included 
Reply with further           
information (n = 14) 
FC +ve  
(n =134) 
FC +ve and no 
further assessment 
(n = 20) 
FC initiated in 
secondary care 
(n = 57)  
Excluded 
FC taken in patient 
with known IBD 
(n = 23) 
Excluded 
FC taken from 
patient <16 years 
(n = 4) 
Excluded 
Included 
FC -ve 
(n =262) 
No reply 
(n = 6) 
Excluded 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flow diagram for patient inclusion in study. (FC faecal calprotectin; IBD inflammatory 
bowel disease; GP general practitioner) 
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Figure 3. Further investigations undertaken in faecal calprotectin positive and negative 
patients. Significant differences shown for numbers of patients undergoing lower 
gastrointestinal (GI) endoscopy, computerized tomography (CT) scan and those not 
investigated (p <0.007 regarded as significant to account for multiple testing). (MRI magnetic 
resonance imaging; VCE video capsule endoscopy; FC Faecal calprotectin) 
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Figure 4a. Receiver operating characteristic (ROC) curve for the diagnosis of inflammatory 
bowel disease using faecal calprotectin testing. Area under the ROC curve = 0.69. 
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Figure 4b. Receiver operating characteristic (ROC) curve for patients tested by measurement 
of faecal calprotectin and with a final diagnosis of organic bowel diseases. Area under the 
ROC curve = 0.76. 
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Figure 5. Average accuracy curve for diagnosis of inflammatory bowel disease at differing 
WKUHVKROGVRIIDHFDOFDOSURWHFWLQµ&XWRII¶LQµg/g faeces.  
 
 
